Study to Evaluate the Efficacy, Safety and Pharmacokinetics of ASB17061 Capsules in Adult Subjects With Atopic Dermatitis

NCT01756898 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

370

Enrollment

INDUSTRY

Sponsor class

Conditions

Atopic Dermatitis

Interventions

DRUG: 5 mg ASB17061
DRUG: Placebo
DRUG: 10 mg ASB17061
DRUG: 20 mg ASB17061

Sponsor

Daiichi Sankyo